Misplaced Pages

This is an old revision of this page, as edited by 82.95.217.180 (talk) at 21:04, 9 April 2011. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Zidovudine

Clinical data
Pregnancy category	AU: B3
Routes of administration	Oral
ATC code	J05AF01 (WHO)
Legal status
Legal status	US: WARNING
Pharmacokinetic data
Bioavailability	near complete absoprtion, following first-pass metabolism systemic availability 65% (range 52 to 75%)
Protein binding	30 to 38%
Metabolism	Hepatic
Elimination half-life	0.5 to 3 hours
Excretion	Renal
Identifiers
IUPAC name 1-((2R,4S,5S)-4-azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-5-methylpyrimidine-2,4(1H,3H)-dione
CAS Number	30516-87-1
PubChem CID	35370
DrugBank	DB00495
ChemSpider	32555
UNII	4B9XT59T7S
KEGG	D00413
ChEMBL	ChEMBL129
CompTox Dashboard (EPA)	DTXSID8020127
ECHA InfoCard	100.152.492
Chemical and physical data
Formula	C10H13N5O4
Molar mass	267.242 g/mol g·mol
3D model (JSmol)	Interactive image
SMILES O=C/1NC(=O)N(\C=C\1C)2O((\N==)C2)CO
InChI InChI=1S/C10H13N5O4/c1-5-3-15(10(18)12-9(5)17)8-2-6(13-14-11)7(4-16)19-8/h3,6-8,16H,2,4H2,1H3,(H,12,17,18)/t6-,7+,8+/m0/s1 Key:HBOMLICNUCNMMY-XLPZGREQSA-N
(what is this?)  (verify)

Zidovudine (INN) or azidothymidine (AZT) (also called ZDV) is a nucleoside analog reverse transcriptase inhibitor (NRTI), a type of antiretroviral drug used for the treatment of HIV/AIDS. It is an analog of thymidine.

AZT was the first approved treatment for HIV, sold under the names Retrovir and Retrovis. AZT use was a major breakthrough in AIDS therapy in the 1990s that significantly altered the course of the illness and helped destroy the notion that HIV/AIDS was a death sentence. AZT slows HIV spread significantly, but does not stop it entirely. This allows HIV to become AZT-resistant over time, and for this reason AZT is usually used in conjunction with other NRTIs and anti-viral drugs. In this form, AZT is used as an ingredient in Combivir and Trizivir, among others. Zidovudine is included in the World Health Organization's "Essential Drugs List", which is a list of minimum medical needs for a basic health care system.

History

Development

In the 1950s the theory that most cancers were caused by environmental retroviruses gained currency. It had long been known that most avian cancers were caused by retroviruses, but this knowledge was of limited use in clinical settings due to a lack of drugs that were effective against them. The development of the first anti-retroviral drugs in the 1950s and 60s led to increasing efforts to isolate the expected human analogs of these avian viruses, and then develop suitable drugs to kill them and produce a universal cure for cancer. These efforts eventually culminated in the "War on Cancer" in the 1970s.

Jerome Horwitz of the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine first synthesized AZT in 1964 under a US National Institutes of Health (NIH) grant. Development was shelved after it proved insufficiently effective against tumors in mice. In 1974, Wolfram Ostertag of the Max Planck Institute in Germany reported that AZT was active against Friend murine leukaemia virus, a retrovirus, in a mouse culture system.

The anti-retroviral approach to develop a "silver bullet" cancer cure ultimately failed. Contrary to early belief, today it is estimated that viruses account for only 10 to 20% of human cancers. However, these efforts advanced the knowledge of cancer considerably, and led to rapid development of many anti-retroviral drugs, which would later prove useful. Zidovudine (AZT) was approved for marketing by the U.S. Food and Drug Administration (FDA) on March 20, 1987.

HIV

In 1984, shortly after the human immunodeficiency virus (HIV) had been confirmed as the cause of AIDS, scientists at the Burroughs-Wellcome Company (now GlaxoSmithKline) began searching for compounds to treat the disease. Burroughs-Wellcome had expertise in viral diseases, led by researchers including Gertrude Elion, David Barry, Paul (Chip) McGuirt Jr., Philip Furman, Martha St. Clair, Janet Rideout, Sandra Lehrman and others. Their research efforts focused on the viral enzyme reverse transcriptase. Reverse transcriptase is an enzyme that retroviruses, including HIV, utilize to replicate themselves. Scientists at Burroughs-Wellcome began to identify and synthesize compounds and developed a screen to test for activity against murine (mouse) retroviruses. One compound, coded "BW A509U", was tested and demonstrated potent activity against mouse viruses.

At the same time, Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan of the United States National Cancer Institute (NCI) had initiated an independent program to develop therapies for HIV/AIDS. The Burroughs-Wellcome scientists were not working directly with HIV, so the two groups began a collaboration. In February 1985, the NCI scientists showed that BW A509U, one of 11 compounds sent to them by Burroughs-Wellcome, had potent activity against HIV in the test tube. Several months later, Broder, Mitsuya, and Yarchoan started the initial phase 1 clinical trial of AZT at the NCI, in collaboration with scientists from Burroughs-Wellcome and Duke University. This trial suggested that the drug could be safely administered to patients with HIV and that it could increase CD4 counts in HIV-infected patients.

A placebo-controlled randomized trial of AZT was subsequently conducted by Burroughs-Wellcome. The study found that AZT could prolong the life of patients with AIDS. Burroughs-Wellcome filed for a patent for AZT in 1985. The United States Food and Drug Administration (FDA) approved the drug (via the then-new FDA accelerated approval system) for use against HIV, AIDS, and AIDS Related Complex (ARC, a now-defunct medical term for pre-AIDS illness) on March 20, 1987. The time between the first demonstration that AZT was active against HIV in the laboratory and its approval was 25 months, one of the shortest periods of drug development in recent history.

AZT was subsequently approved as a preventive treatment in 1990. It was initially administered in much higher dosages than today, typically 400 mg every four hours (even at night). However, the unavailability at that time of alternatives to treat AIDS affected the risk/benefit ratio, with the certain toxicity of HIV infection outweighing the risk of drug toxicity. One of AZT's side effects is anemia, a common complaint in early trials.

Current treatment regimens involve lower dosages (e.g., 300 mg) of AZT taken twice a day, almost always as part of highly active antiretroviral therapy (HAART). AZT is combined with other drugs in order to prevent mutation of HIV into an AZT-resistant form.

AZT crystallizes in a monoclinic structure, forming a hydrogen bonded network of base-paired dimers; its crystal structure was reported in 1988.

Prophylaxis

AZT may be used as post-exposure prophylaxis in combination with other antiretroviral medications, substantially reducing the risk of HIV infection following a significant exposure to the virus (such as a needle-stick injury involving blood or body fluids from an individual known to be infected with HIV).

AZT is also recommended as part of a regimen to prevent mother-to-child transmission of HIV during pregnancy, labor, and delivery. With no treatment, approximately 25% of infants whose mothers are infected with HIV will become infected. AZT has been shown to reduce this risk to approximately 8% when given in a three-part regimen during pregnancy, delivery and to the infant for 6 weeks after birth. During the period from 1994 to 1999 when this was the primary form of prevention of mother-to-child HIV transmission, AZT prophylaxis prevented more than 1000 infant HIV infections. Use of appropriate combinations of antiretroviral medications, cesarean section and avoidance of breast feeding can further reduce mother-child transmission of HIV to 1–2%.

Side effects

Chronic, high-dose therapy with AZT is associated with significant side effects, including anemia, neutropenia, hepatotoxicity, cardiomyopathy, and myopathy. Damage to muscle cells is reversible upon cessation of AZT treatment has been attributed to several possible causes including depletion of mitochondrial DNA, sensitivity of the γ-DNA polymerase in the cell mitochondria, the depletion of thymidine triphosphate, oxidative stress, reduction of intracellular L-carnitine or apoptosis of the muscle cells. Anemia due to AZT can be treated using erythropoietin to stimulate red blood cell production. Drugs that inhibit hepatic glucuronidation, such as indomethacin, acetylsalicylic acid (Aspirin) and trimethoprim, decrease the elimination rate and increase the toxicity of the drug. Minor side effects include nausea and vomiting, headache, changes in the distribution of body fat, sleep disruption and loss of appetite while less common but potentially serious side effects include discoloration of fingernails and toenails, mood changes, tingling or numbness of the hands or feet, easy bruising or bleeding and seizures. Serious allergic reactions are rare.

Viral resistance

Even at very high doses, AZT does not destroy the HIV infection, but only delays the replication of the virus and the progression of the disease. During prolonged AZT treatment, HIV has the ability to gain an increased resistance to AZT by mutation of its reverse transcriptase. To slow the development of resistance, physicians generally recommend that AZT be given in combination with another reverse transcriptase inhibitor and an antiretroviral from another group, such as a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor; this type of therapy is known as HAART (Highly Active Anti Retroviral Therapy). AZT has been shown to work additively or synergistically with many antiviral agents such as acyclovir and interferon; however, ribavirin decreases the antiviral effect of AZT.

Mode of action

Like other reverse transcriptase inhibitors, AZT works by inhibiting the action of reverse transcriptase, the enzyme that HIV uses to make a DNA copy of its RNA. Reverse transcription is necessary for production of the viral double-stranded DNA, which is subsequently integrated into the genetic material of the infected cell (where it is called a provirus).

The azido group increases the lipophilic nature of AZT, allowing it to cross cell membranes easily by diffusion and thereby also to cross the blood-brain barrier. Cellular enzymes convert AZT into the effective 5'-triphosphate form. Studies have shown that the termination of the formed DNA chains is the specific factor in the inhibitory effect.

The triphosphate form also inhibits DNA polymerase used by human cells to undergo cell division, but has approximately 100-fold greater affinity for viral reverse transcriptase. Because of this selectivity, in vitro studies have shown that AZT inhibits HIV replication without affecting the function of normal T cells. The cellular DNA polymerase used by mitochondria to replicate is more sensitive to the inhibitory effects of AZT, accounting for its toxic effects on cardiac and skeletal muscles, causing myositis.

Patent issues

The patents on AZT have been the target of some controversy. In 1991, Public Citizen filed a lawsuit claiming that the patents were invalid. Subsequently, Barr Laboraties and Novopharm Ltd. also challenged the patent, in part based on the assertion that NCI scientists Samuel Broder, Hiroaki Mitsuya, and Robert Yarchoan should have been named as inventors, and those two companies applied to the FDA to sell AZT as a generic drug. In response, Burroughs Wellcome Co. filed a lawsuit against the two companies. The United States Court of Appeals for the Federal Circuit ruled in 1992 in favor of Burroughs Wellcome, claiming that even though they had never tested it against HIV, they had conceived of it working before they sent it to the NCI scientists. In 2002, another lawsuit was filed over the patent by the AIDS Healthcare Foundation.

However, the patent expired in 2005 (placing AZT in the public domain), allowing other drug companies to manufacture and market generic AZT without having to pay GlaxoSmithKline any royalties. The U.S. FDA has since approved four generic forms of AZT for sale in the U.S.

In November 2009 GlaxoSmithKline formed a joint venture with Pfizer which combined the two companies' HIV assets in one company called ViiV Healthcare. This included the rights to Zidovudine.

References

1. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.
2. "WHO Model List of Essential Medicines" (PDF). World Health Organization. March 2005. Retrieved 2006-03-12.{{cite web}}: CS1 maint: year (link)
3. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 20018391, please use {{cite journal}} with |pmid=20018391 instead.
4. Horwitz, JP (1964). "The monomesylates of 1-(2-deoxy-bd-lyxofuranosyl) thymines". Org. Chem. Ser. Monogr. 29 (7): 2076–9. doi:10.1021/jo01030a546. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
5. Detours V; Henry D (writers/directors) (2002). I am alive today (history of an AIDS drug) (Film). ADR Productions/Good & Bad News.
6. "A Failure Led to Drug Against AIDS". The New York Times. 1986-09-20. Retrieved 2010-06-30.
7. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 4531031 , please use {{cite journal}} with |pmid= 4531031 instead.
8. ^ Cimons, Marlene (21 March 1987). "U.S. Approves Sale of AZT to AIDS Patients". Los Angeles Times. p. 1.
9. ^ Mitsuya H, Weinhold K, Furman P, St Clair M, Lehrman S, Gallo R, Bolognesi D, Barry D, Broder S (1985). "3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro". Proc Natl Acad Sci USA. 82 (20): 7096–100. doi:10.1073/pnas.82.20.7096. PMC 391317. PMID 2413459.{{cite journal}}: CS1 maint: multiple names: authors list (link)
10. ^ Yarchoan R, Mitsuya H, Myers C, Broder S (1989). "Clinical pharmacology of 3'-azido-2',3'-dideoxythymidine (zidovudine) and related dideoxynucleosides". N Engl J Med. 321 (11): 726–38. doi:10.1056/NEJM198909143211106. PMID 2671731.{{cite journal}}: CS1 maint: multiple names: authors list (link)
11. ^ Yarchoan R, Klecker R, Weinhold K, Markham P, Lyerly H, Durack D, Gelmann E, Lehrman S, Blum R, Barry D (1986). "Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex". Lancet. 1 (8481): 575–80. doi:10.1016/S0140-6736(86)92808-4. PMID 2869302.{{cite journal}}: CS1 maint: multiple names: authors list (link)
12. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mildvan D, Schooley RT; et al. (1987). "The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial". N Engl J Med. 317 (4): 185–91. doi:10.1056/NEJM198707233170401. PMID 3299089. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
13. De Clercq E (1994). "HIV resistance to reverse transcriptase inhibitors". Biochem Pharmacol. 47 (2): 155–69. doi:10.1016/0006-2952(94)90001-9. PMID 7508227.
14. Yarchoan R, Mitsuya H, Broder S (1988). "AIDS therapies". Sci Am. 259 (4): 110–9. doi:10.1038/scientificamerican1088-110. PMID 3072667.{{cite journal}}: CS1 maint: multiple names: authors list (link)
15. Dyer I, Low JN, Tollin P, Wilson HR, Howie RA (1988). "Structure of 3'-azido-3'-deoxythymidine, AZT". Acta Crystallogr C. 44 ( Pt 4): 767–9. PMID 3271074. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
16. "Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HIV". Retrieved 2006-03-29.
17. "Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health" (PDF). Retrieved 2006-03-29.
18. Connor E, Sperling R, Gelber R, Kiselev P, Scott G, O'Sullivan M, VanDyke R, Bey M, Shearer W, Jacobson R (1994). "Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group". N Engl J Med. 331 (18): 1173–80. doi:10.1056/NEJM199411033311801. PMID 7935654.{{cite journal}}: CS1 maint: multiple names: authors list (link)
19. Walensky RP, Paltiel AD, Losina E; et al. (2006). "The survival benefits of AIDS treatment in the United States". J. Infect. Dis. 194 (1): 11–9. doi:10.1086/505147. PMID 16741877. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
20. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 20544523, please use {{cite journal}} with |pmid= 20544523 instead.
21. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18504416 , please use {{cite journal}} with |pmid= 18504416 instead.
22. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9402140, please use {{cite journal}} with |pmid=9402140 instead.
23. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 12524467 , please use {{cite journal}} with |pmid=12524467 instead.
24. "ZIDOVUDINE (AZT) - ORAL (Retrovir) side effects, medical uses, and drug interactions". MedicineNet. Retrieved 2006-01-09.
25. "zidovudine, Retrovir". Medicinenet.com. 2010-08-12. Retrieved 2010-12-14.
26. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 2186629, please use {{cite journal}} with |pmid=2186629 instead.
27. Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 15855480, please use {{cite journal}} with |pmid=15855480 instead.
28. Mitsuya H, Yarchoan R, Broder S (1990). "Molecular targets for AIDS therapy". Science. 249 (4976): 1533–44. doi:10.1126/science.1699273. PMID 1699273.{{cite journal}}: CS1 maint: multiple names: authors list (link)
29. Furman P, Fyfe J, St Clair M, Weinhold K, Rideout J, Freeman G, Lehrman S, Bolognesi D, Broder S, Mitsuya H (1986). "Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase". Proc Natl Acad Sci USA. 83 (21): 8333–7. doi:10.1073/pnas.83.21.8333. PMC 386922. PMID 2430286.{{cite journal}}: CS1 maint: multiple names: authors list (link)
30. Collins M, Sondel N, Cesar D, Hellerstein M (2004). "Effect of nucleoside reverse transcriptase inhibitors on mitochondrial DNA synthesis in rats and humans". J Acquir Immune Defic Syndr. 37 (1): 1132–9. doi:10.1097/01.qai.0000131585.77530.64. PMID 15319672.{{cite journal}}: CS1 maint: multiple names: authors list (link)
31. Parker W, White E, Shaddix S, Ross L, Buckheit R, Germany J, Secrist J, Vince R, Shannon W (1991). "Mechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase and human DNA polymerases alpha, beta, and gamma by the 5'-triphosphates of carbovir, 3'-azido-3'-deoxythymidine, 2',3'-dideoxyguanosine and 3'-deoxythymidine. A novel RNA template for the evaluation of antiretroviral drugs". J Biol Chem. 266 (3): 1754–62. PMID 1703154.{{cite journal}}: CS1 maint: multiple names: authors list (link)
32. Rang H.P., Dale M.M., Ritter J.M. (1995). Pharmacology (3 ed.). Pearson Professional Ltd. ISBN 0-443-05974-8.{{cite book}}: CS1 maint: multiple names: authors list (link)
33. Balzarini J, Naesens L, Aquaro S, Knispel T, Perno C, De Clercq E, Meier C (1 December 1999). "Intracellular metabolism of CycloSaligenyl 3'-azido-2', 3'-dideoxythymidine monophosphate, a prodrug of 3'-azido-2', 3'-dideoxythymidine (zidovudine)". Mol Pharmacol. 56 (6): 1354–61. PMID 10570065.{{cite journal}}: CS1 maint: multiple names: authors list (link)
34. US Court of Appeals for the Federal Circuit. "Burroughs Wellcome Co. v. Barr Laboratories, 40 F.3d 1223 (Fed. Cir. 1994)". University of Houston -- Health Law and Policy Institute. Retrieved 2007-02-28.

External links

• U.S. National Library of Medicine: Drug Information Portal - Zidovudine

• Nucleoside analog reverse transcriptase inhibitors
• World Health Organization essential medicines
• IARC Group 2B carcinogens
• Azides
• Tetrahydrofurans
• Pyrimidinediones